Rhythm Pharma wins Canadian nod for weight loss therapy
May 08, 2023 8:53 AM ETRhythm Pharmaceuticals, Inc. (RYTM)By: Dulan Lokuwithana, SA News Editor1 Comment
porcorex
- Rhythm Pharmaceuticals (NASDAQ:RYTM) announced Monday that Health Canada approved its weight management agent Imcivree as a subcutaneous injection for patients aged six years and older with certain rare genetic diseases of obesity.
- Accordingly, Imcivree will be indicated for those with obesity due to Bardet-Biedl syndrome (BBS) and certain patients with deficiencies of biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR).
- The approval follows a priority review conducted by Health Canada on late-stage data for Imcivree in obesity due to BBS as well as POMC, PCSK1, and LEPR deficiencies. Rhythm (RYTM) expects to launch the product in Canada in the coming months.
- Read: In August 2022, Goldman Sachs upgraded the commercial-stage biotech to Buy from Neutral, citing the potential of Imcivree, also known as setmelanotide.